A citation-based method for searching scientific literature

Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold, László Sipos, Roelien H Enting, Pim J French, Winand N M Dinjens, Charles J Vecht, Anouk Allgeier, Denis Lacombe, Thierry Gorlia, Khê Hoang-Xuan. J Clin Oncol 2013
Times Cited: 714



Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran, Minesh Mehta. J Clin Oncol 2013
Times Cited: 667




List of shared articles



Times cited

Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Grace S Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo,[...]. Cancer Res Treat 2022
0

Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
Julia Cluceru, Yannet Interian, Joanna J Phillips, Annette M Molinaro, Tracy L Luks, Paula Alcaide-Leon, Marram P Olson, Devika Nair, Marisa LaFontaine, Anny Shai,[...]. Neuro Oncol 2022
5

Back to the Future: Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past.
Michelle M Kim, Jona A Hattangadi-Gluth, Kristin J Redmond, Daniel M Trifiletti, Scott G Soltys, Michael T Milano. Int J Radiat Oncol Biol Phys 2022
0

Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.
Antonio Dono, Kristin Alfaro-Munoz, Yuanqing Yan, Carlos A Lopez-Garcia, Zaid Soomro, Garret Williford, Takeshi Takayasu, Lindsay Robell, Nazanin K Majd, John de Groot,[...]. Neurosurgery 2022
0

Predictive accuracy of T2-FLAIR mismatch sign for the IDH-mutant, 1p/19q noncodeleted low-grade glioma: An updated systematic review and meta-analysis.
Yoon Ah Do, Se Jin Cho, Byung Se Choi, Sung Hyun Baik, Yun Jung Bae, Leonard Sunwoo, Cheolkyu Jung, Jae Hyoung Kim. Neurooncol Adv 2022
0

Innovating Strategies and Tailored Approaches in Neuro-Oncology.
Alberto Picca, David Guyon, Orazio Santo Santonocito, Capucine Baldini, Ahmed Idbaih, Alexandre Carpentier, Antonio Giuseppe Naccarato, Mario Caccese, Giuseppe Lombardi, Anna Luisa Di Stefano. Cancers (Basel) 2022
0

Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Martin C Tom, Michael T Milano, Samuel T Chao, Scott G Soltys, Jonathan P S Knisely, Arjun Sahgal, Seema Nagpal, Simon S Lo, Siavash Jabbari, Tony J C Wang,[...]. Radiother Oncol 2022
0

Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics.
Saivenkat Vagvala, Jeffrey P Guenette, Camilo Jaimes, Raymond Y Huang. Cancer Imaging 2022
2

Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
J Bryan Iorgulescu, Chuxuan Sun, Corey Neff, Gino Cioffi, Catherine Gutierrez, Carol Kruchko, Jennifer Ruhl, Kristin Waite, Serban Negoita, Jim Hofferkamp,[...]. Neuro Oncol 2022
1

Surgical Neuro-Oncology: Management of Glioma.
Dana Mitchell, Jack M Shireman, Mahua Dey. Neurol Clin 2022
0

Disconnecting multicellular networks in brain tumours.
Varun Venkataramani, Matthias Schneider, Frank Anton Giordano, Thomas Kuner, Wolfgang Wick, Ulrich Herrlinger, Frank Winkler. Nat Rev Cancer 2022
0

Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.
Nayan Lamba, Malia McAvoy, Vasileios K Kavouridis, Timothy R Smith, Mehdi Touat, David A Reardon, J Bryan Iorgulescu. Neurooncol Pract 2022
1

Lung toxicity of lomustine in the treatment of progressive gliomas.
Corinna Seliger, Christina Nürnberg, Wolfgang Wick, Antje Wick. Neurooncol Adv 2022
0

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
A Wick, A Sander, M Koch, M Bendszus, S Combs, T Haut, A Dormann, S Walter, M Pertz, J Merkle-Lock,[...]. BMC Cancer 2022
0

A Population-Based Study of Treatment and Survival in Older Glioma Patients.
Anne S Reiner, Stephanie M Lobaugh, Selin Gonen, Eli L Diamond, Katherine S Panageas. JNCI Cancer Spectr 2022
1

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.
Craig Horbinski, Tamar Berger, Roger J Packer, Patrick Y Wen. Nat Rev Neurol 2022
0

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, Alba A Brandes, J Gregory Cairncross, Johan M Kros, Lynn S Ashby, Martin J B Taphoorn, Luis Souhami, Winand N M Dinjens,[...]. J Clin Oncol 2022
0

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
Anna-Luisa Luger, Sven König, Patrick Felix Samp, Hans Urban, Iris Divé, Michael C Burger, Martin Voss, Kea Franz, Emmanouil Fokas, Katharina Filipski,[...]. J Neurooncol 2022
0

Update on Radiation Therapy for Central Nervous System Tumors.
Rifaquat Rahman, Erik Sulman, Daphne Haas-Kogan, Daniel N Cagney. Hematol Oncol Clin North Am 2022
1

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Nimish A Mohile, Hans Messersmith, Na Tosha Gatson, Andreas F Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson,[...]. J Clin Oncol 2022
7

Radiation guidelines for gliomas.
D Antoni, L Feuvret, J Biau, C Robert, J-J Mazeron, G Noël. Cancer Radiother 2022
0

Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.
Gabrielle Metz, Dasantha Jayamanne, Helen Wheeler, Matthew Wong, Raymond Cook, Nicholas Little, Jonathon Parkinson, Marina Kastelan, Chris Brown, Michael Back. BMC Neurol 2022
0

Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Jasmin Jo, Martin J van den Bent, Burt Nabors, Patrick Y Wen, David Schiff. Neuro Oncol 2022
0

Recurrent oligodendroglioma with changed 1p/19q status.
Valeria Barresi, Andrea Mafficini, Martina Calicchia, Maria Liliana Piredda, Angelo Musumeci, Claudio Ghimenton, Aldo Scarpa. Neuropathology 2022
0

Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.
Alexandra McAleenan, Hayley E Jones, Ashleigh Kernohan, Tomos Robinson, Lena Schmidt, Sarah Dawson, Claire Kelly, Emmelyn Spencer Leal, Claire L Faulkner, Abigail Palmer,[...]. Cochrane Database Syst Rev 2022
3


Development and validation of a novel survival prediction model for newly diagnosed lower-grade gliomas.
Qiang Zhu, Yuchao Liang, Ziwen Fan, Yukun Liu, Chunyao Zhou, Hong Zhang, Lei He, Tianshi Li, Jianing Yang, Yanpeng Zhou,[...]. Neurosurg Focus 2022
0

A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas.
Weicheng Zheng, Ruolan Zhang, Ziru Huang, Jianpeng Li, Haonan Wu, Yuwei Zhou, Jinwei Zhu, Xianlong Wang. Front Mol Biosci 2022
0

Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Louis Garnier, Chrystelle Vidal, Olivier Chinot, Elisabeth Cohen-Jonathan Moyal, Apolline Djelad, Charlotte Bronnimann, Lien Bekaert, Luc Taillandier, Jean-Sébastien Frenel, Olivier Langlois,[...]. Oncologist 2022
0

Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Aparna Pallavajjala, Lisa Haley, Victoria Stinnett, Emily Adams, Roshni Pallavajjala, Jialing Huang, Laura Morsberger, Melanie Hardy, Patty Long, Christopher D Gocke,[...]. Hum Pathol 2022
0

Calcium-Related Gene Signatures May Predict Prognosis and Level of Immunosuppression in Gliomas.
Peidong Liu, Yu Li, Yiming Zhang, John Choi, Jinhao Zhang, Guanjie Shang, Bailiang Li, Ya-Jui Lin, Laura Saleh, Liang Zhang,[...]. Front Oncol 2022
0

Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning.
Elisabeth Bumes, Claudia Fellner, Franz A Fellner, Karin Fleischanderl, Martina Häckl, Stefan Lenz, Ralf Linker, Tim Mirus, Peter J Oefner, Christian Paar,[...]. Cancers (Basel) 2022
0

The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis.
Qi Lin, Jia-Hao Bao, Fei Xue, Jia-Jun Qin, Zhen Chen, Zhong-Rong Chen, Chao Li, Yi-Xuan Yan, Jin Fu, Zhao-Li Shen,[...]. Front Oncol 2022
0

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Lia M Halasz, Albert Attia, Lisa Bradfield, Daniel J Brat, John P Kirkpatrick, Nadia N Laack, Nafisha Lalani, Emily S Lebow, Arthur K Liu, Heather M Niemeier,[...]. Pract Radiat Oncol 2022
0

Current and Future Frontiers of Molecularly Defined Oligodendrogliomas.
Jordina Rincon-Torroella, Maureen Rakovec, Josh Materi, Divyaansh Raj, Tito Vivas-Buitrago, Abel Ferres, William Reyes Serpa, Kristin J Redmond, Matthias Holdhoff, Chetan Bettegowda,[...]. Front Oncol 2022
0

The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Kai Zhao, Guochen Sun, Qun Wang, Zhe Xue, Gang Liu, Yirong Xia, Anhui Yao, Yue Zhao, Na You, Chenxuan Yang,[...]. Acad Radiol 2021
4

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul D Brown, Robert B Jenkins, J Gregory Cairncross, Wolfgang Wick, Michael Weller,[...]. Neuro Oncol 2021
24

Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Ruichun Li, Wei Chen, Ping Mao, Jia Wang, Jiangpeng Jing, Qinli Sun, Maode Wang, Xiao Yu. Exp Biol Med (Maywood) 2021
0

Anaplastic Oligodendroglioma - Is Adjuvant Radiotherapy Mandatory following Maximal Surgical Resection?: Grade 3 Oligo Radiotherapy.
Christos Profyris, Emily Chen, Isabella M Young, Kassem Chendeb, Syed A Ahsan, Robert G Briggs, Michael E Sughrue, Charles Teo. Clin Neurol Neurosurg 2021
0

Clinical practice guidelines for the management of adult diffuse gliomas.
Tao Jiang, Do-Hyun Nam, Zvi Ram, Wai-Sang Poon, Jiguang Wang, Damdindorj Boldbaatar, Ying Mao, Wenbin Ma, Qing Mao, Yongping You,[...]. Cancer Lett 2021
69

A basic review on systemic treatment options in WHO grade II-III gliomas.
Maximilian J Mair, Marjolein Geurts, Martin J van den Bent, Anna S Berghoff. Cancer Treat Rev 2021
19

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn, Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven,[...]. Nat Rev Clin Oncol 2021
244

Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.
Marta Padovan, Mario Caccese, Vittorina Zagonel, Giuseppe Lombardi. Anticancer Drugs 2021
0

An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas.
Jingtao Wang, Xuejun Zheng, Jinling Zhang, Hao Xue, Lijie Wang, Rui Jing, Shuo Chen, Fengyuan Che, Xueyuan Heng, Gang Li,[...]. Eur Radiol 2021
11

Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
Iris Divé, Eike Steidl, Marlies Wagner, Katharina Filipski, Michael C Burger, Kea Franz, Patrick N Harter, Oliver Bähr, Emmanouil Fokas, Ulrich Herrlinger,[...]. Oncology 2021
0

Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Vincent Esteyrie, Caroline Dehais, Elodie Martin, Catherine Carpentier, Emmanuelle Uro-Coste, Dominique Figarella-Branger, Charlotte Bronniman, Damien Pouessel, Delphine Larrieu Ciron, François Ducray,[...]. Oncologist 2021
5

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Eike Steidl, Katharina Filipski, Pia S Zeiner, Marlies Wagner, Emmanouil Fokas, Marie-Therese Forster, Michael W Ronellenfitsch, Iris Divé, Joachim P Steinbach, Patrick N Harter,[...]. J Cancer Res Clin Oncol 2021
1

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Rachel J Keogh, Razia Aslam, Maeve A Hennessy, Zac Coyne, Bryan T Hennessy, Oscar S Breathnach, Liam Grogan, Patrick G Morris. BMC Cancer 2021
3


Preoperative Patient-Reported Outcomes in Suspected Low-Grade Glioma: Markers of Disease Severity and Correlations with Molecular Subtypes.
Dongni Buvarp, Isabelle Rydén, Katharina S Sunnerhagen, Thomas Olsson Bontell, Tomás Gómez Vecchio, Anja Smits, Asgeir Store Jakola. J Clin Med 2021
0